用长春新碱、阿霉素和地塞米松治疗原发性（轻链）淀粉样变性引起的肾病综合征。
The treatment of nephrotic syndrome caused by primary (light chain) amyloid with vincristine, doxorubicin and dexamethasone.
作者信息
Wardley A M, Jayson G C, Goldsmith D J, Venning M C, Ackrill P, Scarffe J H
机构信息
Department of Medical Oncology, Christie Hospital, Withington, Manchester, UK.
出版信息
Br J Cancer. 1998 Sep;78(6):774-6. doi: 10.1038/bjc.1998.577.
Abstract
Three out of four patients with primary (light chain) amyloid nephrotic syndrome treated with vincristine, doxorubicin and dexamethasone (VAD) induction obtained a partial response and are alive in continuing remission at 4.1, 6.5 and 9.3 years. These preliminary results are of considerable interest and suggest that prospective evaluation of this regimen is warranted in patients with this condition.
摘要
接受长春新碱、阿霉素和地塞米松（VAD）诱导治疗的四分之三原发性（轻链）淀粉样肾病综合征患者获得了部分缓解，分别在4.1年、6.5年和9.3年时仍存活且处于持续缓解状态。这些初步结果颇受关注，提示对患有该疾病的患者进行该方案的前瞻性评估是有必要的。
相似文献
1
The treatment of nephrotic syndrome caused by primary (light chain) amyloid with vincristine, doxorubicin and dexamethasone.用长春新碱、阿霉素和地塞米松治疗原发性（轻链）淀粉样变性引起的肾病综合征。
Br J Cancer. 1998 Sep;78(6):774-6. doi: 10.1038/bjc.1998.577.
2
Nephrotic syndrome due to primary systemic AL amyloidosis, successfully treated with VAD (vincristine, doxorubicin and dexamethasone) alone.
Intern Med. 2008;47(6):543-9. doi: 10.2169/internalmedicine.47.0709. Epub 2008 Mar 17.
3
Rapid reversal of nephrotic syndrome due to primary systemic AL amyloidosis after VAD and subsequent high-dose chemotherapy with autologous stem cell support.在VAD及随后的高剂量化疗并接受自体干细胞支持后，原发性系统性AL淀粉样变性所致肾病综合征迅速缓解。
Bone Marrow Transplant. 1999 May;23(9):967-9. doi: 10.1038/sj.bmt.1701765.
4
5
Regression of renal amyloid deposits by VAD therapy plus autologous stem cell transplantation in a patient with primary AL amyloidosis.VAD 疗法联合自体干细胞移植使原发性 AL 淀粉样变性患者的肾淀粉样沉积物消退。
CEN Case Rep. 2020 Feb;9(1):6-10. doi: 10.1007/s13730-019-00416-1. Epub 2019 Sep 14.
7
Therapeutic outcome of cyclic VAD (vincristine, doxorubicin and dexamethasone) therapy in primary systemic AL amyloidosis patients.环磷酰胺、阿霉素和地塞米松（VAD）疗法对原发性系统性AL淀粉样变性患者的治疗效果。
Intern Med. 2008;47(17):1517-22. doi: 10.2169/internalmedicine.47.0949. Epub 2008 Sep 1.
8
A rare lung nodule consisting of adenocarcinoma and amyloid deposition in a patient with primary systemic AL amyloidosis.一名原发性系统性AL淀粉样变性患者出现的罕见肺结节，由腺癌和淀粉样沉积组成。
Intern Med. 2011;50(3):243-6. doi: 10.2169/internalmedicine.50.4094. Epub 2011 Feb 1.
9
Extended follow up of high-dose melphalan and autologous stem cell transplantation after vincristine, doxorubicin, dexamethasone induction in amyloid light chain amyloidosis of the prospective phase II HOVON-41 study by the Dutch-Belgian Co-operative Trial Group for Hematology Oncology.荷兰-比利时血液肿瘤学合作试验组针对前瞻性II期HOVON-41研究中，长春新碱、阿霉素、地塞米松诱导治疗后大剂量美法仑和自体干细胞移植在轻链型淀粉样变性中的长期随访。
Haematologica. 2015 May;100(5):677-82. doi: 10.3324/haematol.2014.119198. Epub 2015 Feb 6.
10
Diagnosis and treatment of AL amyloidosis.AL淀粉样变性的诊断与治疗。
Clin Nephrol. 2000 Jun;53(6):417-23.
引用本文的文献
1
Amyloidosis: pathogenesis and new therapeutic options.淀粉样变性：发病机制和新的治疗选择。
J Clin Oncol. 2011 May 10;29(14):1924-33. doi: 10.1200/JCO.2010.32.2271. Epub 2011 Apr 11.
2
How to treat patients with systemic amyloid light chain amyloidosis? Comparison of high-dose melphalan, low-dose chemotherapy and no chemotherapy in patients with or without cardiac amyloidosis.如何治疗系统性轻链淀粉样变性患者？心脏淀粉样变性患者与非心脏淀粉样变性患者接受大剂量美法仑、低剂量化疗与无化疗的比较。
Clin Exp Nephrol. 2011 Aug;15(4):486-92. doi: 10.1007/s10157-011-0426-0. Epub 2011 Mar 9.
3
Successful management of refractory pleural effusion due to systemic immunoglobulin light chain amyloidosis by vincristine adriamycin dexamethasone chemotherapy: a case report.长春新碱、阿霉素、地塞米松化疗成功治疗系统性免疫球蛋白轻链淀粉样变性所致难治性胸腔积液：一例报告
J Med Case Rep. 2010 Oct 18;4:322. doi: 10.1186/1752-1947-4-322.
4
Successful treatment of primary AL amyloidosis by VAD therapy, high-dose melphalan, and autologous peripheral stem cell transplantation.采用VAD疗法、大剂量美法仑及自体外周血干细胞移植成功治疗原发性AL淀粉样变性。
Clin Exp Nephrol. 2009 Oct;13(5):522-525. doi: 10.1007/s10157-009-0198-y. Epub 2009 Jun 5.
本文引用的文献
1
2
Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only.100例原发性淀粉样变性患者的治疗：美法仑、泼尼松和秋水仙碱与仅用秋水仙碱的随机试验。
Am J Med. 1996 Mar;100(3):290-8. doi: 10.1016/s0002-9343(97)89487-9.
3
Primary systemic amyloidosis: clinical and laboratory features in 474 cases.原发性系统性淀粉样变性：474例患者的临床及实验室特征
Semin Hematol. 1995 Jan;32(1):45-59.
4
VAD chemotherapy as remission induction for multiple myeloma.VAD化疗用于多发性骨髓瘤的缓解诱导。
Br J Cancer. 1995 Feb;71(2):326-30. doi: 10.1038/bjc.1995.65.
5
Interaction of the anthracycline 4'-iodo-4'-deoxydoxorubicin with amyloid fibrils: inhibition of amyloidogenesis.蒽环类药物4'-碘-4'-脱氧阿霉素与淀粉样纤维的相互作用：对淀粉样蛋白生成的抑制作用
Proc Natl Acad Sci U S A. 1995 Mar 28;92(7):2959-63. doi: 10.1073/pnas.92.7.2959.
6
Amyloidosis (AL). Clinical and laboratory features in 229 cases.淀粉样变性（AL型）。229例患者的临床及实验室特征。
Mayo Clin Proc. 1983 Oct;58(10):665-83.
7
Primary amyloidosis associated with multiple myeloma. Predictors of successful therapy.
Am J Med. 1986 Mar;80(3):413-8. doi: 10.1016/0002-9343(86)90715-1.
8
Primary systemic amyloidosis. Comparison of melphalan/prednisone versus colchicine.原发性系统性淀粉样变性。美法仑/泼尼松与秋水仙碱的比较。
Am J Med. 1985 Dec;79(6):708-16. doi: 10.1016/0002-9343(85)90521-2.
9
[Treatment of AL amyloidosis without myeloma].
Ann Med Interne (Paris). 1988;139(3):190-3.
10
Diagnostic radionuclide imaging of amyloid: biological targeting by circulating human serum amyloid P component.淀粉样蛋白的诊断性放射性核素成像：循环中的人血清淀粉样蛋白P成分的生物靶向作用
Lancet. 1988 Jun 25;1(8600):1413-8. doi: 10.1016/s0140-6736(88)92235-0.
Zotero 插件